NextCure (NXTC, Financial) is making steady progress with its LNCB74 antibody-drug conjugate program. The company successfully completed the second cohort in April 2025 as part of the dose escalation phase in the Phase 1 clinical trial. Plans are in place to start enrolling backfill cohorts in the latter half of the year, utilizing 10 active sites, with an additional three sites expected to join by May 2025. NextCure anticipates sharing proof of concept data in the first half of 2026 as the study progresses.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for NextCure Inc (NXTC, Financial) is $3.00 with a high estimate of $3.00 and a low estimate of $3.00. The average target implies an upside of 525.00% from the current price of $0.48. More detailed estimate data can be found on the NextCure Inc (NXTC) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, NextCure Inc's (NXTC, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
